Cover Image

Treatment Sequencing and Line of Therapy for Biologics and JAK Inhibitors in Patients With Rheumatoid Arthritis: Implications for Design and Uptake of New Drugs and Predictive Biomarker Diagnostics

Fuente: Wiley Open Access

Saved in:

Bibliographic Details
Main Authors:	Jeffrey R. Curtis, Shanette Daigle, Emily E. Holladay, Yujie Su, Michael George, Gordon Lam, Robert Levin, Priya Reddy, Fenglong Xie, Amy S. Mudano
Format:	Artículo Open Access
Published:	Wiley 2026
Subjects:	Arthritis Care & Research
Online Access:	Acceder al recurso
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Neutrophil Activation Markers and Rheumatoid Arthritis Treatment Response to the JAK1/2 Inhibitor Baricitinib
by: Runa Kuley, et al.
Published: (2024)

Use of a Molecular Signature Response Classifier to Inform Treatment Selection Improves Clinical Disease Activity Among Patients with Rheumatoid Arthritis Initiating a Biologic or Targeted Synthetic Disease‐Modifying Antirheumatic Drug
by: Fenglong Xie, et al.
Published: (2026)

Survival in Immune Checkpoint Inhibitor–Treated Patients With Rheumatoid Arthritis and Non–Small Cell Lung Cancer: An Observational Cohort Study
by: Deanna P. Jannat‐Khah, et al.
Published: (2025)

Incidence of Major Adverse Cardiovascular Events in Patients With Rheumatoid Arthritis Treated With JAK Inhibitors Compared With Biologic Disease‐Modifying Antirheumatic Drugs: Data From an International Collaboration of Registries
by: Romain Aymon, et al.
Published: (2025)

Changes in the Workforce Characteristics of Providers Who Care for Adult Patients With Rheumatologic and Musculoskeletal Disease in the United States
by: Melissa L. Mannion, et al.
Published: (2024)

Real‐World Effectiveness of Pegloticase Associated With Use of Concomitant Immunomodulatory Therapy
by: Emily E. Holladay, et al.
Published: (2024)

Where We Live Matters: Varied Disease Burden and Treatment Patterns in Psoriatic Arthritis in the United States
by: Brittany Banbury, et al.
Published: (2026)

Prevalence of Cardiovascular and Cancer Risk Factors Among Rheumatoid Arthritis Patients Prescribed JAK Inhibitors and Tumor Necrosis Factor Inhibitors: A Cross‐Sectional Study
by: Jud C. Janak, et al.
Published: (2024)

Peripheral Biomarker Signatures in Rheumatoid Arthritis–Associated Interstitial Lung Disease
by: Austin M. Wheeler, et al.
Published: (2025)

Fine particulate matter constituents, ozone, and systemic lupus erythematosus: A large general‐population cohort analysis with extended quantile g‐computation
by: Naizhuo Zhao, et al.
Published: (2026)

The Risk of Lung Cancer in Rheumatoid Arthritis and Rheumatoid Arthritis–Associated Interstitial Lung Disease
by: Rebecca T. Brooks, et al.
Published: (2024)

Effect of Recent Antirheumatic Drug on Features of Rheumatoid Arthritis–Associated Lymphoproliferative Disorders
by: Yoshihiko Hoshida, et al.
Published: (2024)

Integrative Multiomics Approaches Identify Biomarkers Associated With Progression From Arthralgia to Rheumatoid Arthritis
by: Min Li, et al.
Published: (2026)

Air Pollution's Hidden Toll: Risks for Rheumatoid Arthritis and Rheumatoid Arthritis–Associated Lung Disease
by: Sofia Ajeganova, et al.
Published: (2025)

Machine Learning to Predict Remission Between 6 and 24 Months in Rheumatoid Arthritis: Insights From JAK, an International Registry Collaboration
by: Zubeyir Salis, et al.
Published: (2026)

Metabolic Syndrome, Adipokines, and Response to Advanced Therapies in Rheumatoid Arthritis
by: Joshua F. Baker, et al.
Published: (2024)

Preferences for Tapering Biologic Disease‐Modifying Antirheumatic Drugs Among People With Rheumatoid Arthritis: A Discrete Choice Experiment
by: Suz Jack Chan, et al.
Published: (2024)

Serum Proteomic Signatures of Rheumatoid Arthritis Risk and Response: Analysis of a Rheumatoid Arthritis Interception Trial
by: Marianna Jasenecova, et al.
Published: (2026)

Another Notch in the Belt of Rheumatoid Arthritis
by: Stephanie R. Zack, et al.
Published: (2024)

Associations of Fire Smoke and Other Pollutants With Incident Rheumatoid Arthritis and Rheumatoid Arthritis–Associated Interstitial Lung Disease
by: Vanessa L. Kronzer, et al.
Published: (2025)

Limited Diagnostic and Prognostic Value of Routine Radiographs in Newly Presenting Arthritis Suspected of Rheumatoid Arthritis: A Retrospective Study
by: Evy Ulijn, et al.
Published: (2024)

Metabolic Consequences of Rheumatoid Arthritis
by: Stevie Barry, et al.
Published: (2025)

Biologic and Targeted Synthetic Disease‐Modifying Antirheumatic Drugs Do Not Arrest Bone Loss in Patients With Rheumatoid Arthritis: A Long‐Term Multicenter Observational Study
by: Takafumi Aritomi, et al.
Published: (2026)

Risk of Venous Thromboembolism With Tofacitinib Versus Tumor Necrosis Factor Inhibitors in Cardiovascular Risk‐Enriched Rheumatoid Arthritis Patients
by: Christina Charles‐Schoeman, et al.
Published: (2024)

Pulmonary Damage Biomarkers for Risk of Rheumatoid Arthritis–Associated Interstitial Lung Disease: Enabling Early Detection and Risk Stratification
by: Pierre‐Antoine Juge, et al.
Published: (2024)

Combining Three Peripheral Blood Biomarkers to Stratify Rheumatoid Arthritis–Associated Interstitial Lung Disease Risk
by: Kelsey Coziahr, et al.
Published: (2026)

Reply
by: Sharon Dowell, et al.
Published: (2026)

The Influence of Race, Ethnicity and Historical Redlining on Psoriatic Disease Burden and Clinical Outcomes
by: Sharon Dowell, et al.
Published: (2025)

Late‐Onset Rheumatoid Arthritis and Air Pollution in the Multiethnic Cohort
by: Anna H. Wu, et al.
Published: (2026)

Evidence of Site‐Specific Mucosal Autoantibody Secretion in Rheumatoid Arthritis
by: Veerle F. A. M. Derksen, et al.
Published: (2024)

Identifying Predictive Biomarkers of Response in Patients With Rheumatoid Arthritis Treated With Adalimumab Using Machine Learning Analysis of Whole‐Blood Transcriptomics Data
by: Chuan Fu Yap, et al.
Published: (2025)

Financial Distress and Its Determinants in Rheumatoid Arthritis
by: Amber Brown Keebler, et al.
Published: (2025)

Utilization of Biologic Disease‐Modifying Antirheumatic Therapy in Patients With Rheumatoid Arthritis and Recently Diagnosed Breast Cancer
by: Juan I. Ruiz, et al.
Published: (2024)

Associations Between Changes in Pain Sensitization and Disease Activity Following Disease‐Modifying Antirheumatic Drug Therapy in Established Rheumatoid Arthritis
by: Burcu Aydemir, et al.
Published: (2025)

Two Birds, One Stone: Lung Cancer Screening in Patients With Rheumatoid Arthritis Identifies Malignancy and Rheumatoid Arthritis–Associated Lung Disease
by: Amir A. Razmjou, et al.
Published: (2026)

Accuracy of Diagnostic Codes and Algorithms Used to Identify Rheumatoid Arthritis and Juvenile Idiopathic Arthritis in Administrative Claims and Electronic Health Records: Systematic Review and Meta‐Analysis
by: Constanza Saka‐Herrán, et al.
Published: (2026)

Performance of the Predicting Risk of Cardiovascular Disease Events Calculator in Rheumatoid Arthritis
by: Tate M. Johnson, et al.
Published: (2026)

A Phase 2 Trial of Hydroxychloroquine in Individuals at Risk for Rheumatoid Arthritis
by: Kevin D. Deane, et al.
Published: (2026)

Association of Clonal Hematopoiesis With Incident, Late‐Onset, Seropositive Rheumatoid Arthritis
by: Kun Zhao, et al.
Published: (2026)

Ever‐Expanding Connections Between Peptidylarginine Deiminase 4 and Rheumatoid Arthritis
by: Miriam A. Shelef, et al.
Published: (2025)